Chemokine re-acquires compound from PPD
Under the agreement, Chemokine will pay Pharmaceutical Product Development (PPD) $100,000 cash on closing, and up to $2.5 million in milestone payments upon achievement of developmental, regulatory and
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).